For some time, in-silico models to address substance transport into and through the skin are gaining more and more importance in different fields of science and industry.
INTRODUCTION
The importance of substance transport into and through the skin has grown consistently in different fields of science and industry over the past decade. Not only pharmaceutical applications for the local or systemic administration of drugs or applications in the cosmetic industries rely on careful investigations of the underlying transport kinetics, especially regulation authorities such as REACH (Regulation, Evaluation, Authorization and Restriction of Chemicals) (1) request information about characteristics of potential harmful xenobiotic exposure to the human skin (2, 3) .
In-vivo experiments in the field of skin absorption are considered the gold standard but are difficult to perform and evaluate due to the complexity of processes involved and obviously face ethical concerns (4, 5) . Hence, experiments with in-vitro test systems are used frequently to provide this information (6) (7) (8) . In the past, it has been shown repeatedly that these test systems are capable of mimicking the in-vivo situation reasonably (9) (10) (11) .
Many investigations in dermal research are performed under infinite dose conditions. These studies are done by applying a sufficiently large amount of the test formulation to the surface of the skin, so that neither the drug nor any of the vehicular components are appreciably reduced during the course of the experiment. The advantage of this procedure of the application of the vehicle is very reproducible and quasi steady-state conditions may be reached in the stratum corneum (SC) (12) .
Effects caused by rubbing are also avoided. On the other hand, this procedure does not mimic applications as they are done in practice, where typically small quantity of drug preparation (finite dose) is applied on a relatively large area of the skin by massaging.
Today, considerable information about drug distribution within the skin, following infinite dosing, is available. In contrast, the data for finite dosing is rather limited (13) , Data for semisolid drug preparation is also less common than permeation data .
Based on available data (14) it was decided to carry out a study gathering input parameters (SC diffusivity and partition coefficient) with respect to a mathematical model based on experimental results of two different in-vitro test systems, the Saarbruecken penetration model (SB-M) and the Franz diffusion cell (FD-C), using the tape stripping technique (15) . With the help of an in-silico model these input parameters were used to predict the situation in-vivo. Experimental data was examined under infinite dose and finite dose conditions for the aforementioned test systems and in-vivo studies. Finite dosing was carried out on the basis of different guidance documents, which state that finite dosing is given when the amount of ointment applied to the skin is between 1-10 mg/cm² (16) (17) (18) . Consequently, infinite dose conditions were implemented by application of more than 10 mg/cm² of formulation. These procedures were performed with a semisolid drug preparation.
Mathematical models predicting skin absorption have, for some time, been considered as alternatives to experimental investigations by different regulatory agencies (19) (20) (21) . For complex mechanistic models it could be shown that in-vitro infinite and finite dose concentration-depth profiles could be predicted reasonably but require a complex set of input parameters (22) (23) (24) . In contrast, in the current work a sparse parameter one-dimensional diffusion model was used to not only investigate and predict the in-vitro situation but also to predict the in-vivo situation based on input parameters derived from an in-vitro based model. For this purpose, the underlying diffusion equation was solved numerically. First of all, the model was fitted to in-vitro concentration-depth profiles to obtain information about diffusivity and partition coefficient with respect to the SC. Subsequently, in-vitro infinite dose fitting results were used to predict the in-vitro finite dose scenario as conducted successfully before for aqueous formulations (22, 25) . Finally, the model was used to predict invivo concentration-depth profiles for the finite and infinite dose case A positive outcome of the presented study should not only give a better hint on the theory of the drug's diffusion into the SC but most likely be a starting point to reduce experimental work in-vitro and in-vivo. It should therefore reduce costs and time required for the development of semisolid drug formulations and other formulations for dermal application.
Materials and Methods
The following materials and equipment were used: Flufenamic acid (Kali-Chemie The non-steroidal drug flufenamic acid (FFA), solved in a concentration of 0.9% in wool alcohols ointment (German Pharmacopoeia 1999), was used as drug preparation under infinite and finite dose conditions. Prior to the application, the drug preparation was stored at 32°C for one week to allow complete dissolution of the drug in the ointment base. The absence of drug particles was checked by light microscopic investigations.
Skin samples for in-vitro experiments
Skin samples were taken from Caucasian female donors undergoing abdominal surgery with the approval of the ethic committee of the Caritas-Hospital Lebach, Germany. Immediately after excision the subcutaneous fatty tissue was removed using a scalpel. The skin was cut into 10 x 10 cm pieces, wrapped in aluminium foil and stored in polyethylene bags at -26°C until use. The maximum storage time was three months.
Saarbruecken penetration model (SB-M) experiments
Details of the experiments are given in (10) . Briefly, for infinite dosing an ointment layer of at least 2 mm was applied whereas for finite dosing 4-6 mg ointment per cm 2 was evenly spread on the skin surface. All experiments were carried out at a skin surface temperature of 32  1°C for different time intervals (0.5, 1, 3 and 6 hours) at occlusive conditions.
Franz diffusion cell (FD-C) experiments
Details of the experiments are given in (10) . In short, application of the ointment was conducted similar to the procedure described previously (SB-M). As receptor fluid Soerensen phosphate buffer pH 7.4 was used and mixed with a magnetic stirring bar at 500 rpm. To allow equilibration the skin specimen was pre-equilibrated for 30 minutes prior to the application of the formulation. All experiments were carried out as described in the previous section (SB-M).
Horizontal segmentation of the stratum corneum (SC)
To compare the results of both models, the skin was always treated in exactly the same manner at the end of all experiments (10) . First, the remaining ointment was removed by wiping the skin with cotton. Second, the skin was successively stripped with 20 pieces of adhesive tape. In a standardised procedure (pressure: 2 kg for 10 sec), tapes were removed rapidly and combined in 6 pools of 1, 1, 3, 4, 5 and 6 strips for analytical purposes. Due to this procedure, each of the removed cell layers had nearly the same thickness, which had been shown in previous studies in different laboratories (26) (27) (28) . The first tape strip was always discarded because of potential contamination.
In-vivo experiments
6 human volunteers (3 male, 3 female), aged 23 -29 years, from whom informed consent was obtained, participated in the study (10) . They were in good health and had no history of any dermatological disease.
A template of Fixomull The tape-stripping procedure (see the previous section) was performed by exerting the pressure just with the forefinger. To increase reproducibility, the procedure was carried out by the same person according to the AAPS/FDA Workshop report (29) and the Guidance for Industry (30) .
In-vitro release experiments
The release of FFA from the ointment was examined for different concentrations (0.225%, 0.45%, 0.675% and 0.9%) using an infinite dose setup (approximately 0.3 g of applied formulation). For that reason, by means of a FD-C setup, released mass over time across a dialysis membrane (0-6 h, 5 time points) and cellulose membrane (0-53 h, 11-18 time points) was determined, respectively.
Assay method and HPLC-procedure
For a detailed description of the extraction procedure and the HPLC analysis [detection limit 20 ng/ml] see Wagner et al. (10) . The linearity of the HPLC method was checked over a quantification range from 50 to 10,000 ng/ml, providing a good linearity between the area of the UV-absorption peak and the respective concentration with r = 0.999 and an accuracy of 97.8  3.8%.
Determination of diffusivity of FFA in the ointment
As stated before, the release of FFA for different concentrations (0.225%, 0.45%, 0.675% and 0.9%) was examined using a dialysis membrane and a cellulose membrane. To estimate diffusivity D of FFA inside the vehicle the amount released per area Q over time t for initial concentration C0 (assuming a uniform distribution of FFA within the ointment at t=0) was fitted for every single experiment using a nonlinear least squares approach (Eq. 1) (31).
Eq. 1
Since equation 1 only holds true for a loss of initial concentration of approximately up to 30% over time, the general solution (Eq. 2) with thickness of applied ointment layer h (h=2mm) was applied to analyse the impact of a potential loss of initial concentration and ensure valid results with respect to the diffusion coefficient (31).
Eq. 2
Here, the underlying infinite sum was calculated until maximum possible accuracy was reached (comparison to the machine epsilon) (24) .
Diffusion model
The diffusion of FFA from the ointment through the SC was simulated using a onedimensional diffusion model. Three compartments (vehicle, SC, deeper skin layers) were implemented to address different diffusion kinetics of the heterogeneous system for the in-vitro and in-vivo scenario (Fig. S1 ). For every compartment a set of diffusion coefficients and partition coefficients with respect to adjacent compartments was assigned. The underlying diffusion equation (Eq. 3) was solved numerically using an implicit Crank-Nicolson finite differences solver (32).
Eq. 3
Phase transitions were modelled in two steps. First the change of diffusivity at A sufficient spatial resolution at phase transitions is crucial to achieve stable and reasonable results in simulation but can largely slow down the speed of computation.
To overcome this problem while gaining maximum speed of computations a nonuniform grid approach according to (34) was applied. Here, a base space step size of 1 µm was used within every compartment. Towards phase transitions the step size was exponentially decreased to at least 1/10 µm.
Dirichlet boundary conditions and reflecting boundary conditions were implemented to model infinite dosing and finite dosing, respectively.
At the start of the calculation, the concentration in the donor was set to the concentration of the drug in the ointment base as employed in the experiment. The concentration in all other elements was zero.
As basis for calculations the following assumptions were made: The thickness of the SC was assumed to be 15 µm for in-vitro simulations and 17 µm for in-vivo simulations that matches the findings from the tape-stripping procedure. The thickness of the deeper skin layers was assumed to be 2000 µm. The thickness of the donor was calculated from the amount of ointment base applied and the specific density of the ointment base (= 0.836 g/cm³). While the donor could be depleted of the drug, the tissue following the deeper skin layers was assumed to be a perfect sink (the concentration at the end of the deeper skin layers was always zero).
Due to the lack of blood level data no blood compartment was modelled.
Model input parameters, fitting and prediction
Determination of diffusivity in the ointment was performed as mentioned previously.
Diffusivity in the deeper skin layers was computed as the harmonic mean of values taken from the literature (24, 25) (DDSL = 8166.67 µm This procedure was applied to infinite and finite dose data from FD-C and SB-M systems separately. For the in-vivo scenario, only approach 2 was applied.
After comparison of the findings, in a first step the kinetic parameters from the in-vitro infinite dose case were used to predict the in-vitro finite dose scenario -a procedure that could be successfully applied before with the help of complex 2D diffusion models for the simulation of drug release from an aqueous formulation (22, 25) .
In a second step the potential to predict the in-vivo scenario from parameters fitted from the in-vitro case was examined.
Software and programming
The diffusion model was implemented in C++ and compiled using the Apple LLVM version 5.0. Fitting was performed with the R programming language version 2.15.1 (35) . For statistical evaluation GraphPad Prism version 6.0 was used.
Results

Estimation of ointment diffusivity of FFA
No significant differences could be found in the fitting results using Eq. 1 and Eq.2 (relative differences of < 0.01%).
Distribution of fitting results of the diffusion coefficient of FFA in the ointment released over two different membrane systems (dialysis membrane and cellulose membrane) showed significant differences between the two groups (dialysis vs. cellulose membrane) with p=0.02 (Wilcoxon-Mann-Whitney-test). All single fits could be considered highly significant (p<0.01). In comparison to results from the cellulose membrane, release over the dialysis membrane is accelerated by a factor of approximately 1.6.
Since variation of vehicle diffusivity in the given range did not alter concentrationdepth profiles of the SC significantly for various test simulations (e.g. maximum differences in concentration of < 0.01% for late times in the more error prone finite dose scenario), for the subsequent simulations the harmonic mean of all estimated diffusion coefficients with DVehicle = 6583.19 µm 2 /h was used as a model input parameter.
Fitting of in-vitro infinite dose profiles
Experimental results for both FD-C and SB-M showed a characteristic jump in concentration at the Vehicle/SC boundary given a vehicle initial concentration of 7.55 mg/ml (Fig. 1) . Here, concentrations in the upper segment of the SC are slightly higher for the SB-M setup in comparison to the FD-C. Both sets of experiments approach towards steady state, whereas SB-M experiments tend to reach steadystate slower. Average relative standard deviation of experimental data is slightly higher for the FD-C setup (45%) in comparison to the SB-M (38%).
Fitting of SC diffusivity and partition coefficient showed reasonable results with low residual standard errors (Tab. I). Fig. 1 shows results from fitting every data point of all times in total (All times, Tab. I). For both setups individual fittings show higher theoretical permeabilities kp ( ) for early times in comparison to late times with a higher average permeability for the FD-C setup (factor of 2.33 Tab. I).
Fitting of in-vitro finite dose profiles
As for the infinite dose scenario, experimental results for FD-C and SB-M showed a characteristic jump in concentration at the Vehicle/SC boundary (Fig. 2) . 
Prediction of in-vitro finite dose profiles from infinite dose input parameters
Given this evidence, prediction of the in-vitro finite dose scenario from input values gathered from the infinite dose case was carried out and showed reasonable results ( Fig. 2) with low relative absolute errors of the fit (0.63 for FD-C and 0.61 for SB-M).
Drug concentration -SC depth -profiles: In-vivo
In-vivo experimental data showed a characteristic jump of concentration below the initial concentration of the vehicle for all time points (Fig. 3) . Concentration-depth profiles for the infinite and finite dose tend to establish a (pseudo) steady-state after 180 min. To compare the in-vivo situation with in-vitro findings the model was tested on this set of data. Fittings of SC diffusivity and partition coefficient could describe the fate of the substance excellently (Fig. 3, dashed 
Prediction of in-vivo profiles from in-vitro input parameters
In second step, model input parameters taken from the in-vitro infinite dose and finite dose case (All times, Tab. I, Tab. II) were used to predict the in-vivo scenario yielding reasonable average relative errors of the fit (Tab. IV).
For both application scenarios (finite and infinite dose) input values from the SB-M finite dose fittings led to the smallest fitting error (prediction results depicted in Fig.   6 ). Simulations (Fig. 4) lead to reasonable results, especially for short times and concentrations below stratum disjunctum (36) .
Discussion
Fitting results and differences in in-vitro and in-vivo setups
Model fitting results for infinite and finite dose in-vitro studies are in very reasonable agreement with the experimental findings (Fig. 1) . Variation in diffusivity and partition coefficient (All times) can be explained by intra-individual variability in determined parameters from different experiments (37) . Average relative standard deviations of in-vitro and in-vivo concentrations over depth and time do show insignificant differences in variability (32-42% for in-vivo and 36-45% for in-vitro). These observations are in reasonable agreement with findings from literature (37) . As stated before, finite dose experiments show a more semi-infinite nature during the time of application due to the rather low donor depletion (11-17%).
The observed decrease of in-vitro diffusion coefficients over time for finite and infinite scenarios is in reasonable agreement with in-vitro findings from Hansen et al. (24) and even with in-vivo findings of Herkenne et al. (38) . The variation over time might be the result of the prolonged incubation time that can lead to higher data variability and subsequently makes fitting the curves more difficult. In addition, the resistance of the epidermis may have an impact on the curve shape after longer incubation times (13) . In contrast to the addressed diffusivity, variability of the fitted partition coefficient over time did not show a clear trend for both in-vitro systems (Tabs. I, II).
Next, the suitability of the presented in-silico approach to describe the in-vivo situation was investigated. In-vivo fittings of diffusivity and partition coefficient showed lower partition coefficients with values below 1 and high diffusivity and subsequently high theoretical permeabilities. In comparison to experimental data an excellent correlation could be found (Fig. 3, dashed lines) .
Due to the steady-state nature of the concentration-depth profiles after short times fitting results for DSC are prone to error. Therefore, SC diffusivity was set to constant values gathered from in-vitro studies. Fitting results were in good agreement with experimental data (Fig. 3, solid The found differences in partition coefficient between in-vitro and in-vivo studies may be attributed to a potential contamination of skin slabs with subcutaneous fatty tissue during the process of excision of ex-vivo skin samples (solubility of FFA in triglycerides: 7%; solubility of FFA in wool wax ointment: 0.9%) (39) . Therefore, it can be concluded that the presented in-silico model is applicable to in-vitro as well as in-vivo data.
Prediction of the in-vitro finite dose scenario from model input parameters from the infinite dose case
In 2013 for aqueous solutions it could be shown that parameters obtained from the in-vitro infinite dose case are suitable parameters to predict the in-vitro finite dose scenario (22, 25) . The investigations cited employ more complex two-dimensional diffusion models that need a larger set of input parameters (e.g. SC lipid diffusivities, corneocyte diffusivities, SC lipid/corneocyte partition coefficients) in comparison to the model presented. Therefore, the question arose, if these findings also hold true for semi-solid preparations using a less complex diffusion model. We could confirm the findings of the aforementioned works by applying a one-dimensional sparseparameter model for a semi-solid donor formulation. Excellent agreement with experimental data for the prediction of in-vitro finite dosing of the two model systems (FD-C and SB-M) was found (Fig. 2) . This supports the hypothesis that in-vitro predictions of finite dosing might be possible using input parameters from infinite dose experiments.
Prediction of the in-vivo scenario from model input parameters from the in-vitro case
Work on predictions of in-vivo permeation is still scarce. show the potential of in-vitro tape-stripping data to predict the situation in man (41) .
Parameters from the in-vitro and in-vivo case were in reasonable agreement, but also some significant differences were observed. In contrast to the study presented here, only the infinite dose scenario was examined, vehicle diffusivity and resistance of the deeper skin layers were not taken into account and porcine skin was used for in-vitro studies.
In this study, predicted human in-vivo concentration-depth profiles from data obtained from in-vitro cases using human skin showed promising results (Fig. 4) . Short times (15-30 min) could be described excellently but concentrations in superficial SC depths are considerably overpredicted for later times (60-180 min). Obviously, differences in partition coefficients between in-vitro and in-vivo experimental findings yield to the aforementioned discrepancies. Hence, possible alterations of solubility due to preparation of ex-vivo skin samples (e.g. contamination with subcutaneous fatty tissue) should be taken into account when gathering kinetic descriptors from invitro settings to describe the transdermal transport of substances in man.
Mathematical diffusion model
In contrast to analytical solutions of the diffusion equation, numerical approaches can be considered more versatile due to generalization (infinite vs. transient scenario), extendibility (e.g. protein binding, evaporation, blood flow) and complexity (e.g. microscopic models of the SC, multi compartment approaches). The interested reader is kindly referred to overview articles about analytical solutions and numerical approaches in the field of modelling skin transport (13, 42, 43) . However, one major drawback of numerical solutions is often the speed of computation. Due to the high level of optimization (implicit finite differences, non-uniform gridding) the presented model is capable to be incorporated in complex operations, like fitting routines, but still run in high spatial resolution on consumer hardware for reasonable computational times.
Considering the complex nature of the human skin and the underlying transport kinetics, one has to bear in mind the following facts:
 In this study the morphological structure of the SC was simplified as a pseudo-homogenous membrane. This obviously, does not reflect the microscopic structure of the SC. This limitation can be overcome by building more complex microscopic models of the SC (44) but this would increase the number of unknown parameters (23) as well as greatly increase computational complexity, making the model less generally applicable.
 Additional mechanisms, such as binding were not considered but might influence parameters determined from in-vitro parameters as well as the underlying kinetic assumptions (43, 45, 46) .
 In-vivo blood flow was not modelled since no blood level data was available.
This might influence in-vitro in-vivo correlation (47) . The application of in-silico models and the concepts presented in this study, will hopefully lead to an improved prediction of the in-vivo situation and a better understanding of the underlying physicochemical processes. 
Comparison of FD-C and SB-M to gather input parameters to predict in-vivo
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